Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

XRCC1 and ADPRT Polymorphisms Associated with Survival in Breast Cancer Cases Treated with Chemotherapy

  • Ye, Sheng (Department of Oncology, Thyroid and Breast Surgery, the First Affiliated Hospital of Sun Yat-Sen University) ;
  • Rong, Jian (Department of Anesthesiology, Thyroid and Breast Surgery, the First Affiliated Hospital of Sun Yat-Sen University) ;
  • Huang, Shao-Hong (Department of Cardiothoracic Surgery, the Third Affiliated Hospital of Sun-Yat Sen University) ;
  • Zheng, Zhou-San (Department of Oncology, Thyroid and Breast Surgery, the First Affiliated Hospital of Sun Yat-Sen University) ;
  • Yun, Miao (Department of Oncology, Thyroid and Breast Surgery, the First Affiliated Hospital of Sun Yat-Sen University) ;
  • Wang, Shen-Ming (Department of Vasculary, Thyroid and Breast Surgery, the First Affiliated Hospital of Sun Yat-Sen University)
  • Published : 2012.10.31
Download PDF
⟨ Previous Next ⟩

Abstract

Aim: To investigate whether XRCC1 and ADPRT polymorphisms might be associated with outcomes of breast cancer. Methods: A prospective study was conducted with a total of 335 breast cancer patients undergoing chemotherapy consecutively collected from Jan. 2005 to Jan. 2008. Genotyping of XRCC1 and ADPRT polymorphisms was conducted by PCR-RFLP assay. Results: All 335 patients were followed up until death or the end of Jan. 2012, with a median follow-up period of 38.8 (2-64) months. It was shown that the variant genotype of XRCC1 399Gln/Gln was strongly significantly associated with a decreased risk of death from breast cancer, with an HR (95% CI) of 0.52 (0.28-0.91). Similarly, individuals carrying the ADPRT 762Ala/Ala demonstrated longer survival compared to ADPRT 762 Val/Val, with an HR (95% CI) of 0.58 (0.31-0.97). Individuals with combination genotypes of XRCC1 399Gln allele and ADPRT 762Ala/Ala presented with a longer survival, the HR (95% CI) being 0.56 (0.32-0.97). Conclusion: We found a significant association between XRCC1399Gln/Gln and ADPRT 762Ala/Ala polymorphisms and clinical outcomes. These two genotypes could be used as a surrogate markers of clinical outcome in glioma cases receiving chemotherapy.

Keywords

References

  1. Ang MK, Patel MR, Yin XY, et al (2011). High XRCC1 protein expression is associated with poorer survival in patients with head and neck squamous cell carcinoma. Clin Cancer Res, 17, 6542-52. https://doi.org/10.1158/1078-0432.CCR-10-1604
  2. Bewick MA, Conlon MS, Lafrenie RM (2009). Haplotypes of XRCC1 and survival outcome in patients with metastatic breast cancer. Breast Cancer Res Treat, 117, 667-9. https://doi.org/10.1007/s10549-008-0293-x
  3. Brem R, Hall J (2005). XRCC1 is required for DNA single-strand break repair in human cells. Nucleic Acids Res, 33, 2512-20. https://doi.org/10.1093/nar/gki543
  4. Engin AB, Karahalil B, Karakaya AE, et al (2011). Association between XRCC1 ARG399GLN and P53 ARG72PRO polymorphisms and the risk of gastric and colorectal cancer in Turkish population. Arh Hig Rada Toksikol, 62, 207-14.
  5. Fard-Esfahani P, Fard-Esfahani A, Fayaz S, et al (2011). Association of Arg194Trp, Arg280His and Arg399Gln polymorphisms in X-ray repair cross-complementing group 1 gene and risk of differentiated thyroid carcinoma in Iran. Iran Biomed J, 15, 73-8.
  6. Giovannetti E, Pacetti P, Reni M, et al (2011). Association between DNA-repair polymorphisms and survival in pancreatic cancer patients treated with combination chemotherapy. Pharmacogenomics, 12, 1641-52. https://doi.org/10.2217/pgs.11.109
  7. Gonçalves A, Finetti P, Sabatier R, et al (2011). Poly(ADPribose) polymerase-1 mRNA expression in human breast cancer: a meta-analysis. Breast Cancer Res Treat, 127, 273-81. https://doi.org/10.1007/s10549-010-1199-y
  8. Guo W, Zhou RM, Wan LL, et al (2008). Polymorphisms of the DNA repair gene xeroderma pigmentosum groups A and C and risk of esophageal squamous cell carcinoma in a population of high incidence region of North China. J Cancer Res Clin Oncol, 134, 263-70.
  9. International Agency for Research on Cancer (2008). Breast Cancer Incidence and Mortality Worldwide in 2008. http://globocan.iarc.fr.
  10. Kang J, D'Andrea AD, Kozono D (2012). A DNA Repair Pathway- Focused Score for Prediction of Outcomes in Ovarian Cancer Treated With Platinum-Based Chemotherapy. J Natl Cancer Inst, 204, 670-81.
  11. Kase M, Vardja M, Lipping A, et al (2011). Impact of PARP-1 and DNA-PK expression on survival in patients with glioblastoma multiforme. Radiother Oncol, 101, 127-31. https://doi.org/10.1016/j.radonc.2011.06.024
  12. Keith, WC (2003). XRCC1 and DNA strand break repair. DNA Repair, 2, 955-69. https://doi.org/10.1016/S1568-7864(03)00118-6
  13. Khrunin AV, Moisseev A, Gorbunova V, et al (2010). Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients. Pharmacogenomics J, 10, 54-61. https://doi.org/10.1038/tpj.2009.45
  14. Kudo K, Gavin E, Das S, et al (2012). Inhibition of Gli1 results in altered c-Jun activation, inhibition of cisplatin-induced upregulation of ERCC1, XPD and XRCC1, and inhibition of platinum-DNA adduct repair. Oncogene, 2011, 610.
  15. Liao WY, Shih JY, Chang GC, et al (2012). Genetic polymorphism of XRCC1 Arg399Gln is associated with survival in nonsmall-cell lung cancer patients treated with gemcitabine/platinum. J Thorac Oncol, 7, 973-81. https://doi.org/10.1097/JTO.0b013e31824fe98c
  16. Liu Y, Chen H, Chen L, et al (2012). Prediction of genetic polymorphisms of DNA repair genes XRCC1 and XRCC3 in the survival of colorectal cancer receiving chemotherapy in the Chinese population. Hepatogastroenterology, 59, 977-80.
  17. Loibl S, Mueller B, Von Minckwitz G, et al (2010). PARP expression in early breast cancer and its predictive value for response to neoadjuvant chemotherapy. J Clin Oncol (Meeting Abstracts), 28, 10511.
  18. Masson M, Niedergang C, Schreiber V, et al (1998). XRCC1 is specifically associated with poly(ADP-ribose) polymerase and negatively regulates its activity following DNA damage. Mol Cell Biol, 18, 3563-71.
  19. Nazarkina ZK, Khodyreva SN, Marsin S, et al (2007). XRCC1 interactions with base excision repair DNA intermediates. DNA Repair (Amst), 6, 254-64. https://doi.org/10.1016/j.dnarep.2006.10.002
  20. Nowsheen S, Bonner JA, Lobuglio AF, et al (2011). Cetuximab augments cytotoxicity with poly (adp-ribose) polymerase inhibition in head and neck cancer. PLoS One, 6, e24148. https://doi.org/10.1371/journal.pone.0024148
  21. Qiao YW, Spitz MR, Shen HB, et al (2002). Modulation of repair of ultraviolet damage in the host-cell reactivation assay by polymorphic XPC and XPD/ERCC2 genotypes. Carcinogenesis, 23, 295-9. https://doi.org/10.1093/carcin/23.2.295
  22. Raabe A, Derda K, Reuther S, et al (2012). Association of single nucleotide polymorphisms in the genes ATM, GSTP1, SOD2, TGFB1, XPD and XRCC1 with risk of severe erythema after breast conserving radiotherapy. Radiat Oncol, 7, 65. https://doi.org/10.1186/1748-717X-7-65
  23. Rodrigues MS, Machado CA, Pagnoncelli D, et al (2011).TP53 and XRCC1 polymorphisms and breast cancer prognosis: a case-case study. Clinics (Sao Paulo), 66, 1097-100. https://doi.org/10.1590/S1807-59322011000600030
  24. Savas S, Kim DY, Ahmad MF, et al (2004). Identifying functional genetic variants in DNA repair pathway using protein conservation analysis. Cancer Epidemiol Biomarkers Prev, 13, 801-7.
  25. Tahara T, Shibata T, Nakamura M, et al (2011). Effect of genetic polymorphisms related to DNA repair and the xenobiotic pathway on the prognosis and survival of gastric cancer patients. Anticancer Res, 31, 705-10.
  26. von Minckwitz G, Mu¨ller B, Loibl S, et al (2010). PARP is expressed in all subtypes of early breast cancer and is a predictive factor for response to neoadjuvant chemotherapy. Eur J Cancer, Suppl 8, 188.
  27. Wu J, Liu J, Zhou Y, et al (2012). Predictive value of XRCC1 gene polymorphisms on platinum-based chemotherapy in advanced non-small cell lung cancer patients: a systematic review and meta-analysis. Clin Cancer Res, 18, 3972-81. https://doi.org/10.1158/1078-0432.CCR-11-1531
  28. Wysham WZ, Mhawech-Fauceglia P, Li H, et al (2012). BRCAness profile of sporadic ovarian cancer predicts disease recurrence. PLoS One, 7, e30042. https://doi.org/10.1371/journal.pone.0030042
  29. Xu C, Wang X, Zhang Y, et al (2011). Effect of the XRCC1 and XRCC3 genetic polymorphisms on the efficacy of platinumbased chemotherapy in patients with advanced non-small cell lung cancer. Zhongguo Fei Ai Za Zhi, 14, 912-7.
  30. Zhao Y, Deng X, Wang Z, et al (2012). Genetic polymorphisms of DNA repair genes XRCC1 and XRCC3 and risk of colorectal cancer in Chinese population. Asian Pac J Cancer Prev, 13, 665-9. https://doi.org/10.7314/APJCP.2012.13.2.665

Cited by

  1. Increased Argonaute 2 Expression in Gliomas and its Association with Tumor Progression and Poor Prognosis vol.15, pp.9, 2014, https://doi.org/10.7314/APJCP.2014.15.9.4079
  2. Three polymorphisms of DNA repair gene XRCC1 and the risk of glioma: a case–control study in northwest China vol.35, pp.2, 2014, https://doi.org/10.1007/s13277-013-1191-3
  3. Association of CYP2E1, STK15 and XRCC1 Polymorphisms with Risk of Breast Cancer in Malaysian Women vol.17, pp.2, 2016, https://doi.org/10.7314/APJCP.2016.17.2.647